Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan
These results suggest that ropegIFN may be cost-effective compared with ruxolitinib in patients with PV who are resistant or intolerant to hydroxycarbamide under the NHI system in Japan.
Authors
- Hiroki Yamaguchi (ORCID: https://orcid.org/0000-0003-2409-7401)
- Shuichi Ota
- Akihiko Gotoh (ORCID: https://orcid.org/0000-0002-8608-4393)
- Hiromi Igari
- Norio Komatsu
- Keita Kirito
- Yuka Sugimoto
- Keigo Hanada
- Tatsunori Murata
Institutions
- Tokyo Medical University (JP)
- Mie University (JP)
- Juntendo University (JP)
- ASKA Pharmaceutical (Japan) (JP)
- Sapporo Hokuyu Hospital (JP)
- Mie University Hospital (JP)
- University of Yamanashi (JP)
- Nippon Medical School (JP)
Publication Details
- Journal
- International Journal of Hematology
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1007/s12185-025-04136-4
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00